In the phase 3 explorer8 study of 148 males aged ≥12 with haemophilia A or B without inhibitors, once-daily subcutaneous concizumab kept median annualised treated bleeding rates low at the 56-week cutoff (A 1.7; B 2.8), with no new safety concerns.
RCTn = 148
Young et al. Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study